What patient population was polivy mainly tested on?

What types of lymphoma does Polivy target most often?
Polivy (polatuzumab vedotin) was studied primarily in adults with diffuse large B-cell lymphoma (DLBCL), the most common aggressive form of non-Hodgkin lymphoma.

How did the trials define “previously untreated” versus “relapsed” patients?
Key studies enrolled two distinct groups: patients newly diagnosed with DLBCL who had not yet received systemic therapy, and patients whose disease had returned or resisted earlier treatments.

Which patient traits were required for trial entry?
Participants needed measurable disease, an ECOG performance status of 0–2, and adequate heart, liver, and kidney function. Those with active central-nervous-system lymphoma or severe neuropathy were excluded.

What age range and health status were represented?
Most patients were 60–70 years old and often had other medical conditions typical for this age group.

Why did researchers focus on DLBCL rather than other lymphomas?
DLBCL accounts for roughly 30 % of all non-Hodgkin lymphomas and has a high unmet need for improved first-line options, making it the logical population for testing Polivy’s benefit-risk profile.

How does the drug compare with standard R-CHOP therapy?
In the POLARIX trial, adding Polivy to R-CHP (replacing vincristine) produced a statistically higher progression-free survival rate than R-CHOP alone, with similar overall survival at the time of analysis.

When does the main patent covering Polivy expire?
The composition-of-matter patent listed on DrugPatentWatch.com is set to expire in 2030, though regulatory exclusivities and potential litigation could shift the exact date of generic or biosimilar entry.